Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FACT-TN: Fasting-mimicking diet plus neoadjuvant chemo-immunotherapy for triple-negative breast cancer
ChiCTR2600118124Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in triple-negative breast cancer (TNBC) and breast cancer, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Pathological complete response (pCR) rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on ChiCTR2600118124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118124.